secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001628280-25-010916
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics reports 2024 net loss $86.6M; cash runway into 2027; key pipeline milestones
--------------------------------------------------------------------------------

- Net loss of $86.6M for FY2024 vs $98.4M in 2023; collaboration revenue $22.6M (down from $34.2M).
- Cash, equivalents and marketable securities $243.7M as of Dec 31, 2024, providing cash runway into 2027.
- FHD-909 Phase 1 trial enrolling for SMARCA4-mutated cancers (NSCLC primary); preclinical combo data at AACR 2025.
- Selective degradation of ARID1B achieved; program update expected in 2025. CBP and EP300 degraders progressing towards IND.
- Research and development expenses $94.5M (down from $109.7M); G&A $28.4M (down from $32.4M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828025010916/0001628280-25-010916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828025010916/fhtx-20250306.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-010916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer